Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results Meeting Abstract
| Authors: | Rugo, H. S.; Borrego, M. R.; Chia, S. K. L.; Juric, D.; Turner, N. C.; Drullinsky, P.; Lerebours, F.; Bianchi, G. V.; Nienstedt, C. C.; Ridolfi, A.; Thuerigen, A.; Ciruelos, E. |
| Abstract Title: | Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 44s |
| Language: | English |
| ACCESSION: | WOS:000487345803685 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.1040 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1040 -- Source: Wos |
